Staidson BioPharm(300204)2025-01-15 08:04Financial Performance - The company expects a net loss attributable to shareholders of approximately 14,766.76 million CNY for the year 2024, compared to a loss of 39,889.28 million CNY in the previous year[3]. - The projected operating revenue for 2024 is around 29,215.00 million CNY, reflecting a decrease of approximately 19.78% compared to the previous year's revenue of 36,417.54 million CNY[3]. - The net loss after deducting non-recurring gains and losses is estimated at 15,870.58 million CNY for 2024, down from 40,630.28 million CNY in the prior year[3]. - The basic earnings per share are projected to be a loss of 0.31 CNY per share, compared to a loss of 0.84 CNY per share in the previous year[3]. Business Strategy - The company is actively expanding its marketing and market exploration efforts while focusing on new product development, despite a decline in main business revenue due to external factors[5]. - The company has established a subsidiary, Jiangsu Beijietai Biotechnology Co., Ltd., funded by certain R&D projects, and is reversing deferred tax assets related to prior years' deductible losses[5]. Non-Recurring Items - Non-recurring gains and losses for 2024 are expected to be approximately 1,003.47 million CNY, with specific figures to be disclosed in the annual report[5]. Audit and Financial Reporting - The financial data presented is preliminary and has not been audited by the accounting firm, with no discrepancies reported between the company and the auditors regarding the earnings forecast[4].